Drug Trial Radar · NCT06769659
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Mar 11, 2025
Primary completion
Aug 17, 2026
Study completion Sep 23, 2026
Sponsor
- Lead sponsor
- NeuroPro Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.
Conditions
- Epilepsy, Generalized
- Epilepsy, Absence
Interventions
NPT 2042Drug
NPT 2042 is a new drug being developed as an anti-seizure treatment
PlaceboOther
Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizuresTime frame: Up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials, Inc. (CTI)
Little Rock, Arkansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.